Publications by authors named "Joanna Tomiczek-Szwiec"

Objective: To investigate whether Molybdenum blood level is a marker of cancer risk on BRCA1 carriers.

Methods: A prospective cohort study was conducted among 989 initially unaffected women with a BRCA1 mutation. Blood samples were collected to measure molybdenum levels, and participants were followed for an average of 7.

View Article and Find Full Text PDF

Pathogenic mutations in BRCA1 (BReast CAncer gene 1) confer high risks of both breast (up to 70%) and ovarian (up to 40%) cancers. Zinc (Zn) and copper (Cu) are essential for various physiological functions, including antioxidant reactions. Their balance, reflected in the Zn/Cu ratio, plays a crucial role in maintaining redox homeostasis, which is vital for cancer prevention.

View Article and Find Full Text PDF

Breast cancer and ovarian cancer pose a significant risk for BRCA1 carriers, with limited risk-reduction strategies. While improved screening helps in the early detection of breast cancer, preventive measures remain elusive. Emerging evidence suggests a potential link between iodine levels and modulation of cancer risk, but comprehensive studies are scarce.

View Article and Find Full Text PDF

BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key processes in cancer development, including DNA repair, gene expression, and apoptosis.

View Article and Find Full Text PDF
Article Synopsis
  • - BRCA1 mutations significantly raise the chances of developing breast and ovarian cancer, and while environmental factors can also play a role, the specific impact of lead exposure on BRCA1 carriers hasn’t been studied until now.
  • - A study involving 989 BRCA1 mutation carriers in Poland found that elevated blood lead levels (above 13.6 μg/L) are linked to a higher risk of ovarian cancer, with HR values indicating more than triple the risk in univariable analysis.
  • - The research suggests that BRCA1 carriers with high lead exposure may benefit from preventive measures like salpingo-oophorectomy (removal of ovaries and fallopian tubes); however, more studies are needed to confirm this
View Article and Find Full Text PDF

Background: There are several genes associated with ovarian cancer risk. Molecular changes in borderline ovarian tumor (BOT) indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). This study determined the prevalence and association of mutations in BRCA1, BRCA2, PALB2, RAD51C, and CHEK2 with the risk of BOTs.

View Article and Find Full Text PDF

Background: To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation.

Methods: Women with Stage I-III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation.

View Article and Find Full Text PDF

The current cancer testing gene panels tend to be comprehensive rather than site-specific. is one of the genes commonly included in the multi-cancer testing panels. Mutations in confer an increase in the risk for breast cancer, but it is not studied whether or not they predispose to prostate cancer.

View Article and Find Full Text PDF

Background: Breast cancer in men accounts for fewer than 1 % of all breast cancer cases diagnosed in men and women. Genes which predispose to male breast cancer include BRCA1 and BRCA2. The role of other genes is less clear.

View Article and Find Full Text PDF

The aim of the study was to analyze the frequency and magnitude of association of 21 recurrent founder germline mutations in , , , , and genes with ovarian cancer risk among unselected patients in Poland. We genotyped 21 recurrent germline mutations in (9 mutations), (4 mutations), (3 mutations), (2 mutations), and (3 mutations) among 2270 Polish ovarian cancer patients and 1743 healthy controls, and assessed the odds ratios (OR) for developing ovarian cancer for each gene. Mutations were detected in 369 out of 2095 (17.

View Article and Find Full Text PDF

Methylation of the promoter of the BRCA1 gene in DNA derived from peripheral blood cells is a possible risk factor for breast cancer. It is not clear if this association is restricted to certain types of breast cancer or is a general phenomenon. We evaluated BRCA1 methylation status in peripheral blood cells from 942 breast cancer patients and from 500 controls.

View Article and Find Full Text PDF

Background: XRCC2 participates in homologous recombination and in DNA repair. XRCC2 has been reported to be a breast cancer susceptibility gene and is now included in several breast cancer susceptibility gene panels.

Methods: We sequenced XRCC2 in 617 Polish women with familial breast cancer and found a founder mutation.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionge5lvqorg2cr1hve8luqft258a1li390): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once